Adil J. Akhtar
Experienced in Fibrosarcoma

Dr. Adil J. Akhtar

Palliative Medicine | Oncology
Corewell Health
Cancer & Leukemia Center
44344 Dequindre Road, Suite 260, 
Sterling Heights, MI 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
41 Years of Experience
Experienced in Fibrosarcoma
Corewell Health
Cancer & Leukemia Center
44344 Dequindre Road, Suite 260, 
Sterling Heights, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adil Akhtar is a Palliative Medicine specialist and an Oncologist in Sterling Heights, Michigan. Dr. Akhtar has been practicing medicine for over 41 years and is rated as an Experienced provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Lung Adenocarcinoma, Bone Marrow Aspiration, and Gastrostomy. Dr. Akhtar is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Dow University Of Health Sciences Dow Medical College, 1985
Residency
Detroit Medical Center
Specialties
Palliative Medicine
Oncology
Licenses
Internal Medicine in MI
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
Johns Hopkins University School of Medicine
Detroit Medical Center
Hospital Affiliations
Corewell Health William Beaumont University Hospital
Corewell Health Beaumont Troy Hospital
Languages Spoken
English
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Cancer & Leukemia Center
44344 Dequindre Road, Suite 260, Sterling Heights, MI 48314
Call: 586-323-1500
Other Locations
Michigan Healthcare Professionals - Palliative Care
32255 Northwestern Highway, Suite 196, Farmington Hills, MI 48334
Call: 248-871-7252
Cancer & Leukemia Center
53960 Van Dyke Avenue, Shelby Township, MI 48316
Call: 586-323-1500

Additional Areas of Focus

Dr. Akhtar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drug: TL-895
Study Phase: Phase 2
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Drug, Combination product
Study Drug: Tazemetostat
Study Phase: Phase 2
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic Neoplasms
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of LNK01002 in Patients With Malignant Myeloid Hematologic Neoplasms
Enrollment Status: Withdrawn
Publish Date: June 18, 2023
Intervention Type: Drug
Study Drug: LNK01002
Study Phase: Phase 1
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: Sabizabulin, Exemestane, Everolimus, Selective estrogen receptor modulator
Study Phase: Phase 2
View 4 Less Clinical Trials

6 Total Publications

Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Journal: Journal of cancer research and clinical oncology
Published: June 26, 2023
View All 6 Publications
Similar Doctors
Distinguished in Fibrosarcoma
Dr. Scott Schuetze
Oncology
Distinguished in Fibrosarcoma
Dr. Scott Schuetze
Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (25.6 miles away)
734-936-5738
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Schuetze is an Oncologist in Ann Arbor, Michigan. Dr. Schuetze is rated as an Elite provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Angiosarcoma, and Myxoid Liposarcoma.

Distinguished in Fibrosarcoma
Dr. Rashmi Chugh
Oncology | Hematology
Distinguished in Fibrosarcoma
Dr. Rashmi Chugh
Oncology | Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (25.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rashmi Chugh is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Chugh is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Ganglioneuroblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, and Rhabdoid Tumor.

Laura M. Nadeau
Distinguished in Fibrosarcoma
Dr. Laura M. Nadeau
Hematology | Oncology
Distinguished in Fibrosarcoma
Dr. Laura M. Nadeau
Hematology | Oncology

Hematology Oncology Consultants Division Of Michigan Healthcare Professionals PC

3577 West 13 Mile Road, Suite 103, 
Royal Oak, MI 
 (8.0 miles away)
248-288-4500
Experience:
27+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Nadeau is a Hematologist and an Oncologist in Royal Oak, Michigan. Dr. Nadeau has been practicing medicine for over 27 years and is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Adult Immune Thrombocytopenia, Chronic Familial Neutropenia, and Bone Marrow Aspiration. Dr. Nadeau is currently accepting new patients.

VIEW MORE FIBROSARCOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Akhtar's expertise for a condition
ConditionClose
    • Distinguished
    • Anal Cancer
      Dr. Akhtar is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Colorectal Cancer
      Dr. Akhtar is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Akhtar is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Akhtar is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Gastroesophageal Junction Cancer
      Dr. Akhtar is
      Distinguished
      . Learn about Gastroesophageal Junction Cancer.
      See more Gastroesophageal Junction Cancer experts
    • Hemangioma Thrombocytopenia Syndrome
      Dr. Akhtar is
      Distinguished
      . Learn about Hemangioma Thrombocytopenia Syndrome.
      See more Hemangioma Thrombocytopenia Syndrome experts
    View All 14 Distinguished Conditions
    • Advanced
    • Adult Soft Tissue Sarcoma
      Dr. Akhtar is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Akhtar is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Akhtar is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Breast Cancer
      Dr. Akhtar is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Childhood Acute Myeloid Leukemia
      Dr. Akhtar is
      Advanced
      . Learn about Childhood Acute Myeloid Leukemia.
      See more Childhood Acute Myeloid Leukemia experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Akhtar is
      Advanced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    View All 33 Advanced Conditions
    • Experienced
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Akhtar is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Akhtar is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Akhtar is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Akhtar is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Acute Promyelocytic Leukemia
      Dr. Akhtar is
      Experienced
      . Learn about Acute Promyelocytic Leukemia.
      See more Acute Promyelocytic Leukemia experts
    • Alveolar Soft Part Sarcoma
      Dr. Akhtar is
      Experienced
      . Learn about Alveolar Soft Part Sarcoma.
      See more Alveolar Soft Part Sarcoma experts
    View All 109 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Close
        0 / 1000

        Please provide us with the below insurance information:

                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.